A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer

Author： Sridhar Srikala   Canil Christina   Chi Kim   Hotte Sebastien   Ernst Scott   Wang Lisa   Chen Eric   Juhasz Agnes   Yen Yun   Murray Peter   Zwiebel James   Moore Malcolm  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.67, Iss.4, 2011-04, pp. : 927-933

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan

By Nishimura Kazuo  

International Journal of Clinical Oncology, Vol. 18, Iss. 2, 2013-04 ,pp. : 306-313

Springer Publishing Company

Access to resources Recommend Favorite

Phase II Trial Assessing Granulocyte-macrophage—Colony Stimulating Factor, Ketoconazole Plus Mitoxantrone in Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel Treatments

By Amato Robert J.   Saxena Somyata   Stepankiw Mika  

Cancer Investigation, Vol. 31, Iss. 3, 2013-03 ,pp. : 177-182

Informa Healthcare

Access to resources Recommend Favorite

A multicenter phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer: a GINECO study

By Diéras Véronique   Guastalla Jean   Ferrero Jean   Curé Hervé   Weber Béatrice   Winckel Philippe   Lortholary Alain   Mayer Françoise   Paraiso Désiré   Magherini Emmanuelle   Pujade-Lauraine Eric  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 6, 2004-06 ,pp. : 489-495

Springer Publishing Company

Access to resources Recommend Favorite

Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study

By Morales Serafín   Lorenzo Antonio   Ramos Manuel   Ballesteros Pedro   Méndez Miguel   Almanza Concepción   Castellanos Javier   Moreno-Nogueira José   Casal Joaquín   Lizón José   Oltra Amparo   Frau Adolfo   Machengs Ignacio   Galán Antonio   Belón Joaquín   Llorca Cristina  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 1, 2004-01 ,pp. : 75-81

Springer Publishing Company

Access to resources Recommend Favorite

Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer

By Chi K.   Tolcher A.   Lee P.   Rosen P.   Kollmannsberger C.   Papadopoulos K.   Patnaik A.   Molina A.   Jiao J.   Pankras C.   Kaiser B.   Bernard A.   Tran N.   Acharya M.  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 237-244

Springer Publishing Company

Access to resources Recommend Favorite